Global DDI Solutions, Terborchstraat 28 (2026)

14/07/2026

🎙️ New episode of DDI of the Month is here!

is a potent, selective BRAF V600-mutant kinase inhibitor, approved for several malignancies including non-small cell lung cancer and often used in combination with MEK inhibitor . In vitro research raised questions about encorafenib potential to cause drug-drug interactions.

In this episode, host Prof. dr. David Burger sits down with Dr. Joe Piscitelli to discuss the cocktail study his team conducted to answer that question, recently published in Clinical Pharmacology & Therapeutics.

Tune in to find out:
🔹 How the Inje cocktail works, and what sets it apart from other cocktail study designs
🔹 Encorafenib's effects on key CYP450 enzymes
🔹 Whether binimetinib adds to the combination's DDI profile
🔹 Encorafenib's potential impact on drug transporters
🔹 Whether encorafenib can also be a victim of interactions, not just a cause

A must-listen for clinicians, pharmacists, and researchers working on drug-drug interaction management.

🎧 Listen now: https://bit.ly/4aRMTv6

24/06/2026

🔬 The Lung Cancer DDI Manager is expanded with two new drugs!

Encorafenib and binimetinib, two targeted therapies used in BRAF/MEK-inhibition, have been added to the platform.

Both carry clinically relevant DDI risks worth knowing:
• Encorafenib is a strong CYP3A4 inducer with broader enzyme interaction potential
• Binimetinib primarily involves UGT1A1, but caution is still warranted with UGT and transport protein co-medications

Explore the full interaction profiles in the Lung Cancer DDI Manager 👇

🔗 https://bit.ly/4aTbK1x

Find out more about these on our website: https://www.ddimanagers.com/search/lung-cancer

29/04/2026

📊 New data presented at ELCC 2026 in Copenhagen on patient use of the Lung Cancer DDI Manager.

72% of patients surveyed said the tool would help them discuss drug-drug interactions with their healthcare team.

Last month, David Burger presented a poster titled “Patient attitudes towards an expert-based website to screen for drug-drug interactions between lung cancer agents and co-medications“ at the ELCC.

The study evaluated the tool among members of ALK Positive Inc., a US patient association for people with ALK-positive lung cancer. Originally designed for healthcare professionals, the DDI Manager proved equally accessible to patients, who showed a comparable ability to navigate it effectively.

These findings point to a real opportunity: when patients have access to expert-grade resources, they can take a more active role in their own care.

👉 Explore the Lung Cancer DDI Manager: https://bit.ly/4eQd0Fl

10/03/2026

📢 New Publication Alert!

We’re pleased to share that a new scientific paper, “Evaluation of drug-drug interactions associated with metamizole in clinical practice,” has been accepted by Expert Review of Clinical Pharmacology.

The study, led by Dr. Tom Jacobs, was co-authored by GDDIS Director David Burger and our collaborator Laura Nijboer.

Using the DDI Manager , the paper evaluates the occurrence of drug-drug interactions, offering valuable insights for clinicians. This tool helps identify and manage potential interactions efficiently, supporting safer and more informed prescribing decisions.

📖 Read the paper: https://www.tandfonline.com/doi/full/10.1080/17512433.2026.2630755

🔍 Explore the DDI Manager Metamizole: https://bit.ly/4lcwOUw

We invite you to learn more about this important work and how the DDI Manager can assist in clinical practice.

19/12/2025

🎙️ New episode of of the Month is out now

How should P-glycoprotein (P-gp) inhibitors and inducers be classified in clinical practice?

In Episode 9 of DDI of the Month, Prof. dr. David Burger speaks with Dr. Claire Coumau and Dr. Chantal Csajka about their recent Clinical review proposing a practical classification of P-gp modulators—something that has long been missing compared to enzymes.

The discussion covers:
• Why P-gp interactions are difficult to interpret
• How selective probe drugs (digoxin, fexofenadine, dabigatran) were used
• The limitations and clinical relevance of the proposed classification

🎧 Listen to the full episode here: https://bit.ly/4pMt3qF

Address

Terborchstraat 28

8011GG

Website

http://www.global-ddi-solutions.org/

Alerts

Be the first to know and let us send you an email when Global DDI Solutions posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Global DDI Solutions:

Global DDI Solutions